Table 4.

Base case analysis and scenario analysis.

Scenario (drug, mg/day)	Cost	Incre-Cost (CNY)	QALY	IncreQALY	LY	IncreLY	ICER (CNY/LY)	ICUR (CNY/QALY)
Val, 320	54,769		11.82		12.63
Sac, 400	65,066	10,297	11.91	0.09	12.7	0.07	156,820	108,622
Olme, 40	57,058		11.82		12.63
Sac, 400	65,220	7,961	11.92	0.1	12.7	0.07	117,189	81,180
Olme, 20	39,393		11.82		12.63
Sac, 400	65,220	25,827	11.9	0.08	12.69	0.06	444,134	307,528
Placebo	54,769		11.82		12.63
Sac, 400	17,340	−37,428	12.02	0.2	12.77	0.14	−267,216	−185,780
Olme, 20	39,393		11.82		12.63
Sac, 200	42,754	3,362	11.89	0.07	12.68	0.05	66,522	46,046
Placebo	21,727		11.82		12.63
Sac, 200	40,710	18,982	12.01	0.19	12.76	0.13	146,246	101,620
Placebo	21,727		11.82		12.63
Sac, 100	31,389	9,662	12	0.18	12.76	0.12	78,368	54,435
Starting age = 50 years old, time horizon = lifelong
Val, 320	63,101		13.58		14.52
Sac, 400	75,134	12,033	13.73	0.15	14.64	0.12	99,771	79,334
Starting age = 70 years old, time horizon = lifelong
Val, 320	42,520		9.24		9.87
Sac, 400	50,441	7,920	9.28	0.04	9.89	0.02	461,281	191,955

Sac-Val, sacubitril-valsartan; Val, valsartan; Olme, olmesartan.